drugset / Trial / NCT00870571

A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Tablets Under Fed Conditions

NCT00870571

Phase 1 Completed 26 enrolled Actavis Inc.
RandomizedCrossoverOpen-label

Summary

The purpose of this study to assess the single-dose relative bioavailability of Actavis Group hf and Pfizer (Norvasc®) 10 mg amlodipine besylate tablets, under fed conditions.

Timeline

Start
2005-04
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 10 mg

Indications

No indication recorded.